Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received an average recommendation of “Hold” from the eleven brokerages that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $8.08.

Several equities research analysts have recently commented on CLDX shares. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Wednesday, May 31st. ValuEngine downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 3rd. Cowen and Company reissued a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, June 6th. Aegis reissued a “buy” rating on shares of Celldex Therapeutics in a report on Thursday, June 29th. Finally, BidaskClub downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th.

Celldex Therapeutics (NASDAQ CLDX) traded down 1.13% during trading on Wednesday, hitting $2.63. 2,395,893 shares of the stock were exchanged. Celldex Therapeutics has a 1-year low of $2.20 and a 1-year high of $5.02. The firm’s 50 day moving average price is $2.45 and its 200-day moving average price is $2.86. The stock’s market cap is $337.54 million.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. The company had revenue of $3.83 million during the quarter, compared to the consensus estimate of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The firm’s revenue for the quarter was up 175.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.32) EPS. On average, analysts anticipate that Celldex Therapeutics will post ($1.04) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Celldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of “Hold” by Brokerages” was reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/celldex-therapeutics-inc-cldx-given-consensus-recommendation-of-hold-by-brokerages/1559861.html.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in Celldex Therapeutics by 7.8% during the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock valued at $24,143,000 after purchasing an additional 708,095 shares during the last quarter. Meditor Group Ltd lifted its holdings in Celldex Therapeutics by 39.9% during the 2nd quarter. Meditor Group Ltd now owns 5,800,000 shares of the biopharmaceutical company’s stock valued at $14,326,000 after purchasing an additional 1,654,100 shares during the last quarter. State Street Corp lifted its holdings in Celldex Therapeutics by 4.7% during the 1st quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock valued at $16,341,000 after purchasing an additional 202,375 shares during the last quarter. Northern Trust Corp lifted its holdings in Celldex Therapeutics by 12.2% during the 2nd quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock valued at $4,992,000 after purchasing an additional 219,661 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Celldex Therapeutics by 42.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock valued at $6,166,000 after purchasing an additional 508,217 shares during the last quarter. 56.69% of the stock is owned by institutional investors and hedge funds.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.